S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
NASDAQ:URGN

UroGen Pharma Stock Forecast, Price & News

$16.95
-0.19 (-1.11 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.75
$17.34
50-Day Range
$14.31
$18.39
52-Week Range
$14.19
$28.20
Volume38,031 shs
Average Volume156,105 shs
Market Capitalization$354.26 million
P/E RatioN/A
Dividend YieldN/A
Beta1.22
30 days | 90 days | 365 days | Advanced Chart
Receive URGN News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.


UroGen Pharma logo

About UroGen Pharma

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. The firm's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Its approved product Jelmyto (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer respectively. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

402nd out of 1,351 stocks

Pharmaceutical Preparations Industry

198th out of 664 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











UroGen Pharma (NASDAQ:URGN) Frequently Asked Questions

Is UroGen Pharma a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" UroGen Pharma stock.
View analyst ratings for UroGen Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than UroGen Pharma?

Wall Street analysts have given UroGen Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but UroGen Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is UroGen Pharma's next earnings date?

UroGen Pharma is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for UroGen Pharma
.

How were UroGen Pharma's earnings last quarter?

UroGen Pharma Ltd. (NASDAQ:URGN) issued its quarterly earnings results on Wednesday, August, 4th. The company reported ($1.17) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.10) by $0.07. The business had revenue of $13.03 million for the quarter, compared to the consensus estimate of $13 million. UroGen Pharma had a negative net margin of 349.05% and a negative trailing twelve-month return on equity of 127.56%.
View UroGen Pharma's earnings history
.

How has UroGen Pharma's stock been impacted by Coronavirus?

UroGen Pharma's stock was trading at $23.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, URGN shares have decreased by 29.0% and is now trading at $16.95.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for URGN?

1 brokerages have issued 12-month price objectives for UroGen Pharma's shares. Their forecasts range from $40.00 to $50.00. On average, they anticipate UroGen Pharma's stock price to reach $45.00 in the next year. This suggests a possible upside of 165.5% from the stock's current price.
View analysts' price targets for UroGen Pharma
or view top-rated stocks among Wall Street analysts.

Who are UroGen Pharma's key executives?

UroGen Pharma's management team includes the following people:
  • Elizabeth Barrett, President, Chief Executive Officer & Director
  • Molly Henderson, Chief Financial & Accounting Officer
  • Marina Konorty, EVP-Research & Development & Technical Operations
  • Mark P. Schoenberg, Chief Medical Officer
  • Moran Mieron, Director-Research & Pre-Clinical Affairs

What other stocks do shareholders of UroGen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu Biopharma (AYTU).

When did UroGen Pharma IPO?

(URGN) raised $46 million in an initial public offering on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

What is UroGen Pharma's stock symbol?

UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."

Who are UroGen Pharma's major shareholders?

UroGen Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.26%), Credit Suisse AG (5.20%), Zeke Capital Advisors LLC (3.46%), State Street Corp (2.28%), ARK Investment Management LLC (1.51%) and Rice Hall James & Associates LLC (1.16%). Company insiders that own UroGen Pharma stock include Elizabeth A Barrett, Mark Schoenberg, Molly Henderson, Peter P Pfreundschuh and Stephen Mullennix.
View institutional ownership trends for UroGen Pharma
.

Which institutional investors are selling UroGen Pharma stock?

URGN stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Rice Hall James & Associates LLC, Group One Trading L.P., Credit Suisse AG, Goldman Sachs Group Inc., JPMorgan Chase & Co., Millennium Management LLC, and Northern Trust Corp. Company insiders that have sold UroGen Pharma company stock in the last year include Mark Schoenberg, and Peter P Pfreundschuh.
View insider buying and selling activity for UroGen Pharma
or view top insider-selling stocks.

Which institutional investors are buying UroGen Pharma stock?

URGN stock was acquired by a variety of institutional investors in the last quarter, including Zeke Capital Advisors LLC, Morgan Stanley, Morgan Stanley, BlackRock Inc., Bank of America Corp DE, Parametric Portfolio Associates LLC, Meitav Dash Investments Ltd., and Meitav Dash Investments Ltd.. Company insiders that have bought UroGen Pharma stock in the last two years include Elizabeth A Barrett, Mark Schoenberg, and Molly Henderson.
View insider buying and selling activity for UroGen Pharma
or or view top insider-buying stocks.

How do I buy shares of UroGen Pharma?

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UroGen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $16.95.

How much money does UroGen Pharma make?

UroGen Pharma has a market capitalization of $354.26 million and generates $11.80 million in revenue each year. The company earns $-128,480,000.00 in net income (profit) each year or ($5.90) on an earnings per share basis.

How many employees does UroGen Pharma have?

UroGen Pharma employs 187 workers across the globe.

What is UroGen Pharma's official website?

The official website for UroGen Pharma is www.urogen.com.

Where are UroGen Pharma's headquarters?

UroGen Pharma is headquartered at 400 Alexander Park, Princeton NJ, 08540.

How can I contact UroGen Pharma?

UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The company can be reached via phone at (646) 768-9780 or via email at [email protected].


This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.